CAR T cell News and Research

RSS

Nanoparticle-programmed immune cells can slow progression of leukemia in mouse model

Researchers at Fred Hutchinson Cancer Research Center have developed biodegradable nanoparticles that can be used to genetically program immune cells to recognize and destroy cancer cells -- while the immune cells are still inside the body.

17 Apr 2017

City of Hope researchers to highlight basic cancer research and population studies at AACR meeting

City of Hope, a world-renowned independent research and cancer and diabetes treatment center, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research at the Walter E. Washington Convention Center in Washington, D.C., April 1 to 5.

28 Mar 2017

New biomarker 'Bim' could help predict optimal treatment for metastatic melanoma patients

Over the past few years, checkpoint blockade immunotherapies have revolutionized cancer treatment and helped many patients who were previously considered untreatable.

8 Mar 2017

MSK researchers harness power of CRISPR/Cas9 to create more-potent CAR T cells

Researchers from Memorial Sloan Kettering Cancer Center have harnessed the power of CRISPR/Cas9 to create more-potent chimeric antigen receptor (CAR) T cells that enhance tumor rejection in mice.

23 Feb 2017

Study paves way for therapies against myeloid-derived suppressor cells that collude with cancer

Some cells excite the immune system. Others soothe it. Myeloid-derived suppressor cells (MDSCs) are one type of soothing cell, and previous work shows that cancer may specifically boost production of MDSCs as a way to tamp down immune response against tumors. At least that's how it works in mice.

3 Feb 2017

Study shows promising results for treating lymphoma patients with immune cell therapy

Lymphoma is the most common blood cancer. The disease occurs when immune cells called lymphocytes multiply uncontrollably. Cancerous lymphocytes can travel throughout the body and form lymph node tumors.

6 Jan 2017

Fred Hutch’s new Evergreen Fund to promote commercialization of research into lifesaving therapies

Fred Hutchinson Cancer Research Center announced its first-ever grants from its newly established Evergreen Fund to spur researchers' efforts to advance bold ideas toward creating or partnering with a commercial entity.

28 Dec 2016

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson Cancer Research Center today announced the official opening of a first-of-its-kind clinic dedicated to providing innovative immunotherapies for cancer patients in clinical trials.

2 Nov 2016

New study reveals CAR T cells can function as micro-pharmacies for precise therapeutic delivery

There has been much recent excitement about immunotherapy and the use of genetically engineered chimeric antigen receptor (CAR) T cells.

30 Sep 2016

Right dose of CAR T cells and lymphodepletion can achieve good response rates for NHL patients

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy.

9 Sep 2016

T-cell technology could be used to treat ovarian tumors with no adverse effects

With only incremental improvements in ovarian cancer survival over the last 40 years, there is a clear need for new treatment options with long-lasting results. Many researchers have turned toward the development of immunotherapies that direct T-cells to selectively eliminate ovarian tumor cells, but an appropriate therapeutic target for ovarian cancers has remained elusive.

29 Jul 2016

Cancer immunotherapy could treat HIV

A type of immunotherapy that has shown promising results against cancer could also be used against HIV, the virus that causes AIDS.

17 Jul 2016

The Wistar Institute and partners receive HIV cure research grant to test novel immunotherapies

The Wistar Institute is pleased to announce that the National Institutes of Health has awarded a nearly $23 million Martin Delaney Collaboratories for HIV Cure Research grant to the BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, a consortium of top HIV researchers led by co-principal investigators Luis J. Montaner, D.V.M., D.Phil., director of the HIV-1 Immunopathogenesis Laboratory at The Wistar Institute Vaccine Center, and James L. Riley, Ph.D., research associate professor at the Perelman School of Medicine at the University of Pennsylvania.

13 Jul 2016

New strategy treats fatal autoimmune disease without outward off-target effects

In a study with potentially major implications for the future treatment of autoimmunity and related conditions, scientists from the Perelman School of Medicine at the University of Pennsylvania have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system.

4 Jul 2016

New CAR-based therapy using combined cancer target could be effective for solid tumors

Chimeric antigen receptors (CARs), engineered from a patient's own immune cells, have been successful for treating blood cancers, but using CARs for solid tumors has been limited by side effects to normal tissues containing the protein targeted by the engineered cells.

22 Jun 2016

Sylvester researchers test new KTE-C19 therapy for patients with aggressive non-Hodgkin's lymphoma

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are testing a novel cellular immunotherapy approach to treating patients with diffuse large B-cell lymphoma who have failed standard therapy.

25 May 2016

Purdue researchers find potential way to overcome limitations posed by CAR T-cell therapy

Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."

24 May 2016

Experimental therapy has over 90% remission rate for advanced leukemia patients

Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers.

28 Apr 2016

Penn researchers report results of CAR therapy trial in brain cancer patients

Immune cells engineered to seek out and attack a type of deadly brain cancer known as glioblastoma (GBM) were found to have an acceptable safety profile and successfully migrate to and infiltrate tumors, researchers from Penn Medicine and Harvard University reported at the AACR Annual Meeting 2016.

19 Apr 2016

Researchers to discuss on innovative cellular therapies during EBMT meeting

Cellular Therapy is an emerging medical science that is today facing a unique developmental phase, well documented by the outstanding and growing numbers of clinical trials.

30 Mar 2016